2,4-Bis(2-sulfanylethyl)benzene-1,3-dicarboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-Bis(2-sulfanylethyl)benzene-1,3-dicarboxamide
• 英文别名: 2,4-bis(2-sulfanylethyl)benzene-1,3-dicarboxamide
• 化学式: C₁₂H₁₆N₂O₂S₂
• 分子量: 284.4
• InChiKey: DVUSONMWDUCCBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  88.2
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• [EN] METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DES TROUBLES SENSIBLES À LA CYSTÉAMINE
  申请人：THIOGENESIS THERAPEUTICS INC

  公开号：WO2019060634A1

  公开（公告）日：2019-03-28

  The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.

  这项发明涉及治疗囊性氨基酸病和其他对半胱氨酸敏感的疾病的方法，包括在体内给予可转化为半胱氨酸的二硫化物。该方法可以包括向受试者单独给予还原剂，以增加半胱氨酸在给予二硫化物后产生的生物利用度，并延长血浆药代动力学特性。该方法允许受试者体内维持持续的半胱氨酸血浆浓度。
• COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS
  申请人：Thiogenesis Therapeutics, Inc.

  公开号：EP3429573A1

  公开（公告）日：2019-01-23
• METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS
  申请人：Thiogenesis Therapeutics, Inc.

  公开号：EP3684418A1

  公开（公告）日：2020-07-29
• [EN] COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS<br/>[FR] COMPOSITIONS SERVANT À LA LIBÉRATION CONTRÔLÉE DE CYSTÉAMINE ET TRAITEMENT SYSTÉMIQUE DE TROUBLES SENSIBLES À LA CYSTÉAMINE
  申请人：THIOGENESIS THERAPEUTICS INC

  公开号：WO2017161318A1

  公开（公告）日：2017-09-21

  The invention features compositions, methods, and kits containing (i) one or more cysteamine precursor compounds convertible to cysteamine in vivo, and (ii) optionally agents to enhance that conversion, formulated to produce a spectrum of pharmacokinetic profiles of cysteamine that can be tailored to individual patients and diseases. The invention also features varying modes of administration of the therapeutic substances in the treatment of cystinosis and other cysteamine sensitive disorders. In particular, formulations combining active ingredient(s) with pharmaceutical excipients that permit sustained cysteamine plasma concentrations are featured.
• [EN] CYSTEAMINE PRECURSOR COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS<br/>[FR] COMPOSÉS PRÉCURSEURS DE CYSTÉAMINE POUR LE TRAITEMENT D'INFECTIONS À BÊTACORONAVIRUS
  申请人：THIOGENESIS THERAPEUTICS INC

  公开号：WO2021202650A1

  公开（公告）日：2021-10-07

  The invention features the use of cysteamine precursor compounds for the treatment and prophylaxis of severe symptoms of betacoronavirus infections, such as infections by SARS-CoV-2, SARS-CoV-1, MERS-CoV, and related viruses.